Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Brodalumab. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Brodalumab. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Brodalumab. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Brodalumab. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Brodalumab. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Brodalumab. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Brodalumab. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Brodalumab. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Brodalumab. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Brodalumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Brodalumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brodalumab. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Brodalumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Brodalumab. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Brodalumab. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Brodalumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Brodalumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Brodalumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Brodalumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brodalumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Brodalumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brodalumab. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Brodalumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Brodalumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Brodalumab. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Brodalumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Brodalumab. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Brodalumab. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Brodalumab. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Brodalumab. |
| Cladribine | Brodalumab may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Brodalumab. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Brodalumab. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Brodalumab. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Brodalumab. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Brodalumab. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Brodalumab. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Brodalumab. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Brodalumab. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Brodalumab. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Brodalumab. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Brodalumab. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Brodalumab. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Brodalumab. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Brodalumab. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Brodalumab. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Brodalumab. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Brodalumab. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Brodalumab. |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Brodalumab. |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with Brodalumab. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Brodalumab. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Brodalumab. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Brodalumab. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Brodalumab. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Brodalumab. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Brodalumab. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Brodalumab. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Brodalumab. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Brodalumab. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Brodalumab. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Brodalumab. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Brodalumab. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Brodalumab. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carbamazepine is combined with Brodalumab. |
| Vinblastine | The risk or severity of adverse effects can be increased when Vinblastine is combined with Brodalumab. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Brodalumab. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Brodalumab. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Brodalumab. |
| Imatinib | The risk or severity of adverse effects can be increased when Imatinib is combined with Brodalumab. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with Brodalumab. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Brodalumab. |
| Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Brodalumab. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Brodalumab. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Brodalumab. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Brodalumab. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Brodalumab. |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with Brodalumab. |
| Methimazole | The risk or severity of adverse effects can be increased when Methimazole is combined with Brodalumab. |
| Etoposide | The risk or severity of adverse effects can be increased when Etoposide is combined with Brodalumab. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Brodalumab. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Brodalumab. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Brodalumab. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Brodalumab. |
| Prednisolone | The risk or severity of adverse effects can be increased when Prednisolone is combined with Brodalumab. |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with Brodalumab. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Brodalumab. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Brodalumab. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Brodalumab. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Brodalumab. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Brodalumab. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Brodalumab. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Brodalumab. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Doxorubicin is combined with Brodalumab. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Brodalumab. |
| Busulfan | The risk or severity of adverse effects can be increased when Busulfan is combined with Brodalumab. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Brodalumab. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Brodalumab. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Brodalumab. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Brodalumab. |